#USA #San Diego #Robbins LLP #Unicycive Therapeutics #UNCY

Robbins LLP's Alert on Unicycive Therapeutics Class Action

Robbins LLP, the esteemed shareholder rights law firm, has put a spotlight on the ongoing class action lawsuit associated with Unicycive Therapeutics, Inc. This class action pertains to shareholders who bought or acquired Unicycive's securities between December 29, 2025, and June 29, 2026. The firm urges affected investors to take note of the impending lead plaintiff deadline of November 2, 2026.

Understanding the Lawsuit

Unicycive Therapeutics operates within the biotechnology sector, specifically focused on developing treatments for kidney diseases. The lawsuit emerges due to allegations that the company did not properly inspect the manufacturing facilities of a third-party vendor. This oversight led to the failure in addressing critical deficiencies noted by the U.S. Food and Drug Administration (FDA).

Background of the Case

In September 2024, Unicycive submitted a New Drug Application (NDA) for their oxylanthanum carbonate therapy aimed at tackling kidney disease. Following its acceptance by the FDA in November 2024, the journey took a turn when the FDA issued a Complete Response Letter (CRL) in June 2025. The letter called attention to deficiencies tied to a third-party manufacturing vendor. In response, Unicycive convened a Type A meeting with the FDA in October 2025 to discuss the noted compliance issues, leading to the resubmission of their NDA in December 2025.

However, the complaint raises serious concerns that during the designated Class Period, Unicycive failed to disclose crucial information to its investors, such as:
1. The company did not conduct any inspections of its third-party vendor’s facility to confirm adherence to good manufacturing practices.
2. There existed a lack of a reasonable basis to believe that the FDA’s previous concerns were addressed.
3. There was an undisclosed risk of needing more information from the vendor regarding manufacturing processes.

Ultimately, these oversights indicate that Unicycive’s previous positive statements about its operations were not backed by solid information.

Impact on Unicycive’s Stock

On June 30, 2026, Unicycive faced significant backlash when they disclosed that the FDA issued another CRL regarding the resubmitted NDA for oxylanthanum carbonate, citing similar manufacturing deficiencies raised in the initial CRL. This revelation hit the market hard, causing Unicycive’s stock to plummet by $3.01 or 39.1%, ultimately closing at $4.69 per share on unusually high trading volume.

Who Can Participate?

The class action lawsuit is relevant for investors who acquired Unicycive securities within the timeframe of December 29, 2025, to June 29, 2026. Those who suffered losses during this period may be entitled to legal recourse under federal securities laws.

Role of the Lead Plaintiff

A lead plaintiff emerges as the court-appointed investor representing the collective interests of all class members during the litigation process. Interested stockholders are encouraged to connect with Robbins LLP before the approaching November 2, 2026, deadline. Importantly, being a lead plaintiff is not a prerequisite for receiving a potential recovery; investors may choose to remain as absent class members if the case progresses favorably.

Cost to Participate

Robbins LLP stresses that participating in the lawsuit does not involve any cost for investors. The firm operates on a contingency fee basis, ensuring that their representation is accessible to all affected parties.

Why Choose Robbins LLP?

Regarded as a leader in shareholder rights litigation, Robbins LLP has a proven track record in representing investors entangled in securities fraud and derivative actions. With a history of restoring over $2 billion in value to shareholders, they emphasize the importance of transparency from companies to maintain a fair market environment.

To gain updates regarding the outcome of the class action against Unicycive Therapeutics, interested individuals can subscribe to their Stock Watch service for alerts about corporate malfeasance.

For further inquiries regarding the Unicycive Therapeutics, Inc. class action, investors can reach out to Robbins LLP via inquiry submission, email attorney Aaron Dumas, Jr., or call them directly at (800) 350-6003.